Tags

Type your tag names separated by a space and hit enter

Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis.
Am J Nephrol. 1992; 12(5):311-8.AJ

Abstract

The effect of intravenous 1 alpha-hydroxyvitamin D3 [1 alpha(OH)D3] on circulating levels of intact parathyroid hormone (PTH 1-84) and COOH-terminal immunoreactive PTH(PTH 53-84) was examined in 13 patients on chronic hemodialysis. Thirteen patients were treated for 300 days (10 months), 9 patients for 520 days (14 months) and 6 patients for 720 days (2 years) with increasing doses of 1 alpha(OH)D3 intravenously under careful control of plasma Ca2+. Blood samples were obtained 1 week before start of treatment and then at every 2nd week. None of the patients had previously been treated with oral vitamin D metabolites. Intact PTH levels were maximally suppressed after 27-33 weeks of treatment by approximately 73%. At the end of the study periods, PTH 1-84 was still suppressed by 78 +/- 4.3% after 300 days, 78 +/- 8.8% after 520 days and 85 +/- 6.5% after 720 days. Plasma Ca2+ was kept within normal levels, but showed an initial increase from 1.14 +/- 0.03 to 1.27 +/- 0.15 mmol/l, and an adjustment of the doses of 1 alpha(OH)D3 was necessary. The present investigation demonstrated (1) that intravenous administration of the 1-hydroxylated vitamin D metabolite 1 alpha(OH)D3 induced a significant decrease in circulating levels of biologically active intact PTH, and (2) that it was possible to maintain the marked suppression of PTH secretion by intravenous treatment of 1 alpha (OH)D3 for up to 2 years. Hypercalcemia could be avoided by careful monitoring of plasma Ca2+ and adjustment of the doses of 1 alpha(OH)D3.

Authors+Show Affiliations

Medical Department P, Rigshospitalet, University of Copenhagen, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1488999

Citation

Brandi, L, et al. "Long-term Suppression of Secondary Hyperparathyroidism By Intravenous 1 Alpha-hydroxyvitamin D3 in Patients On Chronic Hemodialysis." American Journal of Nephrology, vol. 12, no. 5, 1992, pp. 311-8.
Brandi L, Daugaard H, Tvedegaard E, et al. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol. 1992;12(5):311-8.
Brandi, L., Daugaard, H., Tvedegaard, E., Nielsen, P. K., Egsmose, C., Storm, T., & Olgaard, K. (1992). Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. American Journal of Nephrology, 12(5), 311-8.
Brandi L, et al. Long-term Suppression of Secondary Hyperparathyroidism By Intravenous 1 Alpha-hydroxyvitamin D3 in Patients On Chronic Hemodialysis. Am J Nephrol. 1992;12(5):311-8. PubMed PMID: 1488999.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. AU - Brandi,L, AU - Daugaard,H, AU - Tvedegaard,E, AU - Nielsen,P K, AU - Egsmose,C, AU - Storm,T, AU - Olgaard,K, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 311 EP - 8 JF - American journal of nephrology JO - Am. J. Nephrol. VL - 12 IS - 5 N2 - The effect of intravenous 1 alpha-hydroxyvitamin D3 [1 alpha(OH)D3] on circulating levels of intact parathyroid hormone (PTH 1-84) and COOH-terminal immunoreactive PTH(PTH 53-84) was examined in 13 patients on chronic hemodialysis. Thirteen patients were treated for 300 days (10 months), 9 patients for 520 days (14 months) and 6 patients for 720 days (2 years) with increasing doses of 1 alpha(OH)D3 intravenously under careful control of plasma Ca2+. Blood samples were obtained 1 week before start of treatment and then at every 2nd week. None of the patients had previously been treated with oral vitamin D metabolites. Intact PTH levels were maximally suppressed after 27-33 weeks of treatment by approximately 73%. At the end of the study periods, PTH 1-84 was still suppressed by 78 +/- 4.3% after 300 days, 78 +/- 8.8% after 520 days and 85 +/- 6.5% after 720 days. Plasma Ca2+ was kept within normal levels, but showed an initial increase from 1.14 +/- 0.03 to 1.27 +/- 0.15 mmol/l, and an adjustment of the doses of 1 alpha(OH)D3 was necessary. The present investigation demonstrated (1) that intravenous administration of the 1-hydroxylated vitamin D metabolite 1 alpha(OH)D3 induced a significant decrease in circulating levels of biologically active intact PTH, and (2) that it was possible to maintain the marked suppression of PTH secretion by intravenous treatment of 1 alpha (OH)D3 for up to 2 years. Hypercalcemia could be avoided by careful monitoring of plasma Ca2+ and adjustment of the doses of 1 alpha(OH)D3. SN - 0250-8095 UR - https://www.unboundmedicine.com/medline/citation/1488999/Long_term_suppression_of_secondary_hyperparathyroidism_by_intravenous_1_alpha_hydroxyvitamin_D3_in_patients_on_chronic_hemodialysis_ L2 - https://www.karger.com?DOI=10.1159/000168465 DB - PRIME DP - Unbound Medicine ER -